Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer

计划入组 40 人 · 首次发布于 2012 年 6 月 19 日

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

计划入组 12 人 · 首次发布于 2015 年 9 月 22 日

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

计划入组 39 人 · 首次发布于 2025 年 11 月 17 日

EGFR inhibitors (non-small cell lung cancer)

GSK-2302032A

GFPT2 inhibitors (non-small-cell lung cancer)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Summit Therapeutics Inc.

United States

Baili Tianheng's Novel Bispecific ADC Receives Fifth Breakthrough Therapy Designation for Small Cell Lung Cancer

Whitehawk Data at WCLC 2026 Position PTK7 as Durable, Treatment-Agnostic ADC Target in EGFR Wild-Type NSCLC

Multitude Therapeutics Reports Promising Phase I/II Results for CD44v9-Directed ADC AMT-116 in Advanced Solid Tumors